This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Real-world evidence with SIMPONI® (golimumab) for the treatment of moderately to severely active Ulcerative Colitis

In biologic-naïve and biologic-experienced patients.

Prescribing Information

Length: 04:29

Watch a short video exploring the real-world data for SIMPONI (golimumab) in biologic naive and biologic experienced moderate-to-severe Ulcerative Colitis patients.

SIMPONI is indicated for treatment of moderately to severely active Ulcerative Colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.1

Reference

  1. SIMPONI Summary of Product Characteristics.

More information about SIMPONI® (golimumab):